With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

The cyclical, high-risk, high-reward nature of the biotech industry is on full display in 2024. This industry is centered on using living organisms and bioprocesses for innovative drug development ...